Arrowhead buys Novartis’ RNAi research and development portfolio
The acquisition includes assignment of certain patents and patent applications owned or controlled by the Swiss firm related to RNAi therapeutics. The deal also comprises of an exclusive
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.